Osprey Private Wealth LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 10.2% in the 2nd quarter, Holdings Channel reports. The fund owned 42,607 shares of the company’s stock after acquiring an additional 3,936 shares during the period. Johnson & Johnson accounts for about 2.8% of Osprey Private Wealth LLC’s investment portfolio, making the stock its 10th biggest position. Osprey Private Wealth LLC’s holdings in Johnson & Johnson were worth $10,821,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Massachusetts Wealth Management lifted its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Massachusetts Wealth Management now owns 17,850 shares of the company’s stock worth $4,533,000 after acquiring an additional 75 shares in the last quarter. Smith Group Asset Management LLC grew its stake in Johnson & Johnson by 6.4% during the 2nd quarter. Smith Group Asset Management LLC now owns 159,696 shares of the company’s stock valued at $40,558,000 after purchasing an additional 9,575 shares in the last quarter. Hardworking Capital Advisors LLC increased its holdings in Johnson & Johnson by 4.6% during the 2nd quarter. Hardworking Capital Advisors LLC now owns 3,904 shares of the company’s stock worth $991,000 after purchasing an additional 171 shares during the last quarter. Avid Wealth Partners LLC raised its position in shares of Johnson & Johnson by 8.6% in the 2nd quarter. Avid Wealth Partners LLC now owns 1,235 shares of the company’s stock valued at $314,000 after purchasing an additional 98 shares in the last quarter. Finally, Hodges Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 18.5% during the 2nd quarter. Hodges Capital Management Inc. now owns 23,026 shares of the company’s stock valued at $5,848,000 after buying an additional 3,591 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 63,972 shares of company stock valued at $16,245,605. Corporate insiders own 0.16% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on JNJ
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $270.69 on Friday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $652.34 billion, a price-to-earnings ratio of 31.37, a price-to-earnings-growth ratio of 2.58 and a beta of 0.24. Johnson & Johnson has a twelve month low of $173.33 and a twelve month high of $276.47. The business has a 50 day simple moving average of $255.08 and a 200-day simple moving average of $242.72.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s payout ratio is 62.11%.
Trending Headlines about Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: The FDA granted 510(k) clearance for the MONARCH QUEST 3 robotic bronchoscopy update. The system adds artificial-intelligence-powered planning, navigation and imaging capabilities, strengthening J&J’s position in the expanding robotic-assisted medical-procedure market. Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
- Positive Sentiment: The European Commission approved TECVAYLI combined with daratumumab for relapsed or refractory multiple myeloma. The decision was supported by Phase 3 results showing statistically significant progression-free and overall-survival improvements versus standard treatments, potentially expanding sales of J&J’s oncology portfolio. European Commission approves Johnson & Johnson’s TECVAYLI plus daratumumab
- Positive Sentiment: Analysts continue to favor J&J as a dividend-focused healthcare investment, citing its diversified operations and pipeline strength. Recent quarterly results also showed adjusted earnings and revenue ahead of consensus, with revenue up 6.6% year over year and full-year 2026 earnings guidance maintained at $11.60–$11.75 per share. Merck vs. J&J: Which Healthcare Giant Should Investors Choose?
- Neutral Sentiment: J&J’s potential interest in Seaport Therapeutics highlights continued investor focus on neuroscience and business-development opportunities, but no transaction has been announced. Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
- Negative Sentiment: Patent-protection losses remain a longer-term risk for several established drugs, although new medicines and recent approvals could help offset declining legacy-product sales. Johnson & Johnson Just Sent Shareholders an Important Message About Its Future
Johnson & Johnson Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
